Company intelligence / Profile preview

Safetest Diagnósticos

Belo Horizonte, Minas Gerais, Brazil

Ownership: Private
Development stage: Other

Overview

Safetest develops and commercializes rapid lateral-flow diagnostic tests, including a COVID‑19 antibody test and other infectious disease assays, with stated accuracy >95% and 2‑minute time-to-result for some products; its technology is already commercial and has been used in published clinical/validation studies such as a visceral leishmaniasis rapid test based on the rKDDR‑plus antigen.

Therapeutic areas: Infectious Diseases
Modalities: Device
Industry: Protein Biomarker Diagnostics

Partnerships

Collaboration with academic researchers at Universidade Federal de Minas Gerais on rKDDR‑plus–based visceral leishmaniasis rapid test development and licensingVictory Square Health for COVID‑19 antibody test development and commercialization

Beyond the preview

Go deeper on Safetest Diagnósticos.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Safetest Diagnósticos.

Explore the full profile